Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.41 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.41 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.41 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.41 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.38 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.38 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732933 | 0.98 | LMNA (0.46) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL13799154 | 0.81 | TAAR1 (0.49) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL11577701 | 0.81 | TDP1 (0.56) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL30943786 | 0.80 | LMNA (0.50) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL2528523 | 0.80 | LMNA (0.43) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL31173886 | 0.79 | LMNA (0.48) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL17066188 | 0.78 | LMNA (0.47) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL11669502 | 0.76 | LMNA (0.57) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL15473414 | 0.75 | LMNA (0.44) | LMNAMAPTGAAALDH1A1HSP90AA1 | |
| SCHEMBL24747284 | 0.72 | LMNA (0.62) | LMNAMAPTGAAALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799475-B2 | Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth | NORTHWESTERN UNIVERSITY (US) | 2020-10-13 | — | — | US | claimed |
| US-20180344691-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2018-12-06 | — | — | US | claimed |
| US-20170216249-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2017-08-03 | — | — | US | claimed |
| US-20160089354-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2016-03-31 | — | — | US | claimed |
| US-9126997-B1 | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma | NORTHWESTERN UNIVERSITY (US) | 2015-09-08 | — | — | US | claimed |
| US-20140045938-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2014-02-13 | — | — | US | claimed |
| WO-2009092796-A1 | SYNEPHRINE DERIVATIVES FOR THE TREATMENT OF CANCER | UNIVERSITEIT GENT (BE) | 2009-07-30 | — | — | WO | claimed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | claimed |
| EP-3768324-B1 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | INST NAT SANTE RECH MED (FR) | 2025-11-26 | — | — | EP | disclosed |
| US-20210187105-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | Baxalta GmbH (CH) | 2021-06-24 | — | — | US | disclosed |
| US-10799475-B2 | Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth | NORTHWESTERN UNIVERSITY (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180344691-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180280501-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | BAXALTA INCORPORATED | 2018-10-04 | — | — | US | disclosed |
| US-20170216249-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NORTHWESTERN UNIVERSITY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20030055030-A1 | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | GENT UNIVERSITEIT (BE) | 2003-03-20 | — | — | US | disclosed |
| US-20030055030-A1 | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | GENT UNIVERSITEIT (BE) | 2003-03-20 | — | — | US | disclosed |
| EP-1239850-A1 | USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239850-A1 | USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045693-A1 | USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045693-A1 | USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | GAA 4431/4885HSP90AA1 2227/4885ESR1 3542/4885 |
| US-20180344691-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NR5A1, AR, CYP17A1 | GAA 3102/4885HSP90AA1 589/4885ESR1 151/4885 |
| US-20160089354-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Cancer Cell Growth | NR5A1, AR, CYP17A1 | GAA 2882/4885HSP90AA1 609/4885ESR1 133/4885 |
| US-20030055030-A1 | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | CCL5, C5AR2, CCL2 | GAA 1738/4885HSP90AA1 3737/4885ESR1 2465/4885 |
| US-20180280501-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | MIF, SERPINA6, NR3C1 | GAA 2098/4885HSP90AA1 257/4885ESR1 1328/4885 |
| US-20170216249-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NR5A1, AR, CYP17A1 | GAA 3102/4885HSP90AA1 589/4885ESR1 151/4885 |
| US-20210187105-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | MIF, SERPINA6, NR3C1 | GAA 2098/4885HSP90AA1 257/4885ESR1 1328/4885 |
| US-20140045938-A1 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth | NR5A1, AR, CYP17A1 | GAA 3102/4885HSP90AA1 589/4885ESR1 151/4885 |
| US-10799475-B2 | Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth | NR5A1, AR, CYP17A1 | GAA 3102/4885HSP90AA1 589/4885ESR1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.